Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

80%

4 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 3

4(80.0%)

Phase 2

1(20.0%)

5Total

Phase 3(4)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT05642468Phase 2Terminated

Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis

Role: lead

NCT04336722Phase 3Active Not Recruiting

Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)

Role: lead

NCT05035030Phase 3Recruiting

Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome

Role: lead

NCT03659916Phase 3Completed

Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC

Role: lead

NCT05426733Phase 3Enrolling By Invitation

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia

Role: lead

All 5 trials loaded